TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Cilcare has established Cilcare K.K., a subsidiary in Tokyo, to support its work in Japan and pursue partnerships across Asia-Pacific. The company named Aurore Marie general manager for Japan and Asia; financial terms, staffing plans and specific regional targets were not disclosed in the source report.
French auditory biopharmaceutical company Cilcare has established a Tokyo subsidiary, Cilcare K.K., creating a local base for its Japanese operations and its planned expansion across Asia-Pacific hearing health. The company has named Aurore Marie general manager for Japan and Asia, as it builds on existing Japanese partnerships and more than a decade of engagement in the country.
The company, headquartered in Montpellier, France, said the subsidiary will serve as a platform to accelerate regional partnerships and connect stakeholders in Asia-Pacific with its pharmaceutical and biotechnology network. The announcement does not detail a launch budget, headcount, timetable for hiring, or specific commercial targets for the Tokyo office.
Cilcare said Marie will lead the new operation. She previously played a central role in establishing the company’s presence in Boston and brings experience in auditory science and cross-cultural leadership, according to the report. Cilcare describes its international work as spanning research and development operations in France and the United States, with more than 350 collaborative projects worldwide in auditory science.
The company’s portfolio includes Synapsound AI, which it describes as a proprietary platform for auditory analytics. Cilcare says the technology is designed to identify biomarkers and support earlier detection and characterization of neurological diseases. Those are company descriptions of the platform; the report does not provide independent performance data or clinical outcomes.
The Tokyo office follows a 2024 strategic partnership with Shionogi, covering the co-development and commercialization of Cilcare candidates CIL001 and CIL003. The source report says the partnership demonstrated early traction in Japan, but gives no further details on development timelines, regulatory status, or commercial progress for either candidate.
Tokyo Base Builds on Japan Partnerships
A local subsidiary gives Cilcare a formal operating base in a market where it has worked with universities, experts and industry partners for years. That could make it easier for the company to develop relationships and coordinate regional activity, although the announcement does not specify which new partnerships are planned or how quickly the office will expand.
The move also places the company closer to Japanese collaborators involved in its existing work with Shionogi. Any commercial or health impact will depend on the progress of the relevant research and development programs; the establishment of an office by itself does not establish that a treatment is effective, approved or available to patients.
Cilcare framed Japan as a relevant market because of its aging population and national attention to prevention, healthy aging and quality of life. Hearing loss is also discussed in research on dementia risk. The source report references the 2024 Lancet Commission in that connection, but does not claim that hearing loss is the sole cause of dementia or that Cilcare’s products prevent it.
Popular right now
Apple AirPods Pro 3 Wireless Earbuds with Active Noise Cancellation
Ninja CREAMi 7-in-1 Ice Cream Maker, NC299AMZ
Dyson Ball Animal 3 Upright Vacuum
As an affiliate, we earn on qualifying purchases.
A Decade of Work in Japan
The Tokyo subsidiary is an extension of Cilcare’s prior activity rather than its first involvement in Japan. The company says it has spent more than a decade engaging with Japanese universities and key opinion leaders. Its 2024 agreement with Shionogi established a partnership around CIL001 and CIL003, providing a business relationship that predates the new entity.
The subsidiary is also part of a broader international expansion. Cilcare had previously expanded into North America, including establishing a presence in Boston. The Hearing Review has separately reported on its US clinical trial for a tinnitus drug, expanded research capacity, an updated license agreement with Sanofi, and funding to advance clinical trials in cochlear synaptopathy. Those developments provide company context, but the source report does not say the Tokyo opening changes their status or timelines.
Cilcare acknowledged support from several organizations in connection with its work in Japan: Business France, the French Chamber of Commerce and Industry in Japan, the Enterprise Europe Network, the Occitanie Region and its Tokyo bureau, and the Japan External Trade Organization. The report does not describe the specific form or terms of that support.
“Cilcare is becoming a truly global company, with strong roots in Europe and the United States and now a dedicated presence in Japan. Having a local team in Tokyo positions us to capture the significant opportunities ahead in hearing health.”
— Celia Belline, Cilcare CEO and co-founder
Office Plans and Program Timelines
The announcement leaves several operational details open. Cilcare has not disclosed the subsidiary’s budget, staffing level, opening date beyond the announcement, or measurable targets for expansion in Japan and elsewhere in Asia-Pacific. It is also unclear which new partnerships the Tokyo team will pursue first.
The source report provides no updated milestones for CIL001 or CIL003, including trial progress, regulatory review or potential launch timing. It also does not offer independent evidence about Synapsound AI’s performance. The company’s stated goals and descriptions should not be read as evidence that a product has demonstrated clinical benefit or received regulatory approval.
Regional Work Moves From Tokyo
Marie is expected to lead Cilcare K.K. and develop the company’s activities from Tokyo. The stated next step is to use the subsidiary to build partnerships across Asia-Pacific and connect regional stakeholders with Cilcare’s wider network. The company has not announced a schedule for those efforts or named specific new agreements.
Readers can look for further updates on the company’s collaborations, the development status of CIL001 and CIL003, and any regulatory or clinical milestones. Until Cilcare provides those details, the opening is best understood as an organizational and regional expansion announcement, rather than a change in the confirmed availability of a hearing treatment.
Key Questions
What has Cilcare announced?
Cilcare has established Cilcare K.K., a Tokyo-based subsidiary, to support its Japanese operations and its broader Asia-Pacific expansion plans.
Who will lead the Tokyo subsidiary?
Aurore Marie has been named general manager for Japan and Asia. The company says she previously helped establish its Boston presence.
Does the new office mean a Cilcare treatment is available in Japan?
No availability or approval announcement is included in the source report. It describes the subsidiary and the company’s partnership with Shionogi, but gives no updated regulatory or launch status for CIL001 or CIL003.
What is Cilcare’s existing connection to Japan?
Cilcare says it has worked with Japanese universities and key opinion leaders for more than a decade. It also entered a 2024 strategic partnership with Shionogi covering co-development and commercialization of CIL001 and CIL003.
What details have not been announced?
The report does not specify the subsidiary’s budget, staffing plans, regional targets, new partnership timetable, or updated clinical and regulatory milestones for the company’s candidates.
Source: rss
